Breaking News, Collaborations & Alliances

Isis Earns $10M Biogen Milestone

Advances IND studies for ISIS-BIIB4Rx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen Idec for initiating the investigational new drug (IND)-supporting studies of ISIS-BIIB4Rx, a drug candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease. ISIS-BIIB4Rx is the fourth drug to enter development under the companies’ collaboration. Isis is eligible to receive as much as $249 million in additional milestone payments and a license fee, as well as royalties from sales of I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters